These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 6113584

  • 1. [Long-term treatment of outpatients with depot neuroleptics (author's transl)].
    Saameli W.
    Schweiz Rundsch Med Prax; 1981 Feb 03; 70(6):206-10. PubMed ID: 6113584
    [No Abstract] [Full Text] [Related]

  • 2. [Prophylactic efficacy of long-acting vs. short-acting neuroleptics in schizophrenic out-patients (author's transl)].
    Tegeler J, Lehmann E, Stockschlaeder M.
    Nervenarzt; 1980 Nov 03; 51(11):654-61. PubMed ID: 6109262
    [No Abstract] [Full Text] [Related]

  • 3. [Depot neuroleptics in social psychiatric practice].
    Pruss U, Rose HK, Zechner A.
    Psychiatr Prax; 1984 Jul 03; 11(4):101-8. PubMed ID: 6148764
    [Abstract] [Full Text] [Related]

  • 4. [Effects of depot neuroleptics on pituitary hormone secretion (author's transl)].
    Czernik A, Kleesiek K.
    Nervenarzt; 1979 Aug 03; 50(8):527-33. PubMed ID: 43482
    [No Abstract] [Full Text] [Related]

  • 5. [The psychoprophylactic importance of treatment with depot neuroleptics in schizophrenia].
    Chiriţă V, Stanciu J, Pirozynski T.
    Rev Med Chir Soc Med Nat Iasi; 1989 Aug 03; 93(3):497-500. PubMed ID: 2576888
    [Abstract] [Full Text] [Related]

  • 6. Depot neuroleptic therapy: clinical considerations.
    Remington GJ, Adams ME.
    Can J Psychiatry; 1995 Apr 03; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
    [Abstract] [Full Text] [Related]

  • 7. [Schizophrenia: prophylaxis prevents recurrence. Low dose depot neuroleptics--an exit from the "revolving door" psychiatry].
    Fortschr Med Suppl; 1993 Apr 03; 147():1-15. PubMed ID: 9260317
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Is depot formulation a long-term optimal treatment option?].
    Musch A.
    Med Monatsschr Pharm; 2005 Nov 03; 28(11):414-6. PubMed ID: 16309031
    [No Abstract] [Full Text] [Related]

  • 12. [Treatment of schizophrenia using depot neuroleptics (author's transl)].
    Faltus F, Soucek K.
    Cesk Psychiatr; 1976 Jun 03; 72(3):170-5. PubMed ID: 963807
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ.
    J Clin Psychiatry; 1984 May 03; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [Abstract] [Full Text] [Related]

  • 19. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
    Kilian R, Angermeyer MC.
    Psychiatr Prax; 2004 Apr 03; 31(3):138-46. PubMed ID: 15042477
    [Abstract] [Full Text] [Related]

  • 20. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM, Ereshefsky L.
    J Clin Psychiatry; 1996 Aug 03; 57(8):337-45. PubMed ID: 8752015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.